New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Search
Zongertinib positive results non-small cell lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Meet our team
Meet our team
COPD Patient Survey Infographic
Soaring to save lives
Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Animal Health
Animal Health
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
Major investment for respiratory diseases completed
105 million euros invested into expansion of production facilities in Ingelheim and Dortmund
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
Cardio-Renal-Metabolic
Cardio-Renal-Metabolic Therapeutic Area
Avian influenza prevention at the source
Teshome Mebatsion, Head of Viral Diseases Research at Boehringer Ingelheim, talks about the avian influenza virus, ways of prevention and scenarios for the future.
Retinal health: All eyes on vision loss
Discover how we want to prevent vision loss caused by diabetic retinopathy and other retinal diseases
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
Uncommon_Mutations_Database
New database of published clinical outcomes from patients with uncommon EGFR mutations in advanced NSCLC treated with afatinib is available for global clinician use
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
Collaborating for social impact
Societal challenges require collective action and Making More Health Together is connecting changemakers to drive collaborations for more social impact
New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy